Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Cost of Revenue (2022 - 2024)

Historic Cost of Revenue for Amylyx Pharmaceuticals (AMLX) over the last 3 years, with Q2 2024 value amounting to $8000.0.

  • Amylyx Pharmaceuticals' Cost of Revenue fell 9985.66% to $8000.0 in Q2 2024 from the same period last year, while for Mar 2025 it was $8000.0, marking a year-over-year decrease of 9996.94%. This contributed to the annual value of $6.0 million for FY2024, which is 7660.08% down from last year.
  • According to the latest figures from Q2 2024, Amylyx Pharmaceuticals' Cost of Revenue is $8000.0, which was down 9985.66% from $5.9 million recorded in Q1 2024.
  • In the past 5 years, Amylyx Pharmaceuticals' Cost of Revenue ranged from a high of $9.4 million in Q4 2023 and a low of $8000.0 during Q2 2024
  • Moreover, its 3-year median value for Cost of Revenue was $5.3 million (2023), whereas its average is $4.3 million.
  • In the last 5 years, Amylyx Pharmaceuticals' Cost of Revenue surged by 293372.09% in 2023 and then plummeted by 9985.66% in 2024.
  • Over the past 3 years, Amylyx Pharmaceuticals' Cost of Revenue (Quarter) stood at $2.8 million in 2022, then soared by 231.8% to $9.4 million in 2023, then tumbled by 99.91% to $8000.0 in 2024.
  • Its last three reported values are $8000.0 in Q2 2024, $5.9 million for Q1 2024, and $9.4 million during Q4 2023.